Autologous Dendritic Cells for Treatment of Advanced Cancer — An Update
- 1 January 2001
- book chapter
- Published by Springer Nature
- Vol. 158, 236-248
- https://doi.org/10.1007/978-3-642-59537-0_24
Abstract
Dendritic cells (DC) are commonly viewed as the professional antigen-presenting cell. They capture antigens, migrate to appropriate lymphoid organs and initiate an antigen-specific CD4 and CD8 T cell response. Much is known about DC physiology, and it is now possible to culture, maintain and expand DC from different human sources, including hematopoietic progenitors in bone marrow and peripheral blood. Combined with the detection of an increasing number of tumor-associated antigens and T cell-recognized peptide epitopes, this has led to a new enthusiasm in the field of tumor immunotherapy and to various clinical applications in phase I/II studies on the treatment of different malignancies. This chapter will review the latest developments and give a brief update of the results obtained in studies of advanced melanoma, as well as provide a short overview of published results for other tumors.Keywords
This publication has 82 references indexed in Scilit:
- A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutationEuropean Journal of Immunology, 1999
- Identification of GP100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primaryin vitro immunization with peptide-pulsed dendritic cellsInternational Journal of Cancer, 1998
- Overlapping peptides of melanocyte differentiation antigen melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1International Journal of Cancer, 1998
- Dendritic cells: from ontogenetic orphans to myelomonocytic descendantsImmunology Today, 1996
- A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytesEuropean Journal of Immunology, 1996
- Current therapy for cutaneous melanomaJournal of the American Academy of Dermatology, 1995
- Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunology Today, 1995
- A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3European Journal of Immunology, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991